Danish pharmaceutical giant Novo Nordisk , maker of popular weight-loss drug Ozempic , announced on Friday that CEO Lars Fruergaard Jorgensen will step down, citing ongoing "market challenges" and a significant drop in the company’s share value.
The board and Jorgensen reached a mutual decision to initiate a leadership transition. He will remain in his role temporarily to "support a smooth transition to new leadership", according to the company.
“The changes are, however, made in light of the recent market challenges Novo Nordisk has been facing, and the development of the company’s share price since mid-2024,” the company said in a statement. The board and Jorgensen “have jointly concluded that initiating a CEO succession is in the best interest of the company and its shareholders," it added.
The decision comes as Novo Nordisk grapples with a sharp decline in its stock price- down more than 50 per cent since June 2024. This was after the stock value had experienced a dramatic surge following the launch of both Wegovy and the diabetes medication Ozempic, with both products containing semaglutide as their primary active component.
Then, sShares fell a further three per cent on the Copenhagen exchange following Friday's CEO exit announcement.
The company recently downgraded its annual sales growth projection, adjusting the forecast from 16-24 per cent to 13-21 per cent. The revision is attributed to rising competition, particularly from compounded versions of its GLP-1 drugs Wegovy and Ozempic, produced in American pharmacies during a recent supply shortage.
However, the US regulators, even though had declared the shortage over in February and ordered an end to compounding, the impact continues to be felt. Novo Nordisk stated it is “actively focused on preventing unlawful and unsafe compounding.”
The firm also faces increasing pressure from US rival Eli Lilly , whose weight-loss injection Zepbound is gaining traction in the same market. A research paper published in the New England Journal of Medicine on Sunday revealed that individuals achieved greater weight reduction whilst using Eli Lilly's rival medication Zepbound.
Additionally, the announcement of successful clinical trials for Eli Lilly's diabetes and obesity medication orforglipron caused Novo Nordisk's share prices to decline significantly last month.
Diabetes affects more than 10 percent of people globally, and treatments for this condition remain central to Novo Nordisk's pharmaceutical operations. The International Diabetes Federation projects a 46 percent rise in adult diabetes cases by 2045.
Additionally, the World Obesity Federation anticipates that by 2035, obesity and overweight conditions will affect over 50 percent of global population, potentially resulting in annual economic consequences exceeding $4 trillion.
The board and Jorgensen reached a mutual decision to initiate a leadership transition. He will remain in his role temporarily to "support a smooth transition to new leadership", according to the company.
“The changes are, however, made in light of the recent market challenges Novo Nordisk has been facing, and the development of the company’s share price since mid-2024,” the company said in a statement. The board and Jorgensen “have jointly concluded that initiating a CEO succession is in the best interest of the company and its shareholders," it added.
The decision comes as Novo Nordisk grapples with a sharp decline in its stock price- down more than 50 per cent since June 2024. This was after the stock value had experienced a dramatic surge following the launch of both Wegovy and the diabetes medication Ozempic, with both products containing semaglutide as their primary active component.
Then, sShares fell a further three per cent on the Copenhagen exchange following Friday's CEO exit announcement.
The company recently downgraded its annual sales growth projection, adjusting the forecast from 16-24 per cent to 13-21 per cent. The revision is attributed to rising competition, particularly from compounded versions of its GLP-1 drugs Wegovy and Ozempic, produced in American pharmacies during a recent supply shortage.
However, the US regulators, even though had declared the shortage over in February and ordered an end to compounding, the impact continues to be felt. Novo Nordisk stated it is “actively focused on preventing unlawful and unsafe compounding.”
The firm also faces increasing pressure from US rival Eli Lilly , whose weight-loss injection Zepbound is gaining traction in the same market. A research paper published in the New England Journal of Medicine on Sunday revealed that individuals achieved greater weight reduction whilst using Eli Lilly's rival medication Zepbound.
Additionally, the announcement of successful clinical trials for Eli Lilly's diabetes and obesity medication orforglipron caused Novo Nordisk's share prices to decline significantly last month.
Diabetes affects more than 10 percent of people globally, and treatments for this condition remain central to Novo Nordisk's pharmaceutical operations. The International Diabetes Federation projects a 46 percent rise in adult diabetes cases by 2045.
Additionally, the World Obesity Federation anticipates that by 2035, obesity and overweight conditions will affect over 50 percent of global population, potentially resulting in annual economic consequences exceeding $4 trillion.
You may also like
Manipur govt extends services of 10,500 Village Defence Force personnel
Blackbuck poaching case: Rajasthan govt challenges acquittal of Saif, Tabu and others in HC; hearing on July 28
Microsoft says it provided AI to Israeli military for war but denies use to harm people in Gaza
Tesla blocks stockholders with less than 3% shares from suing officers on its behalf
"Welcoming step": JD(U)'s KC Tyagi on reports of India's diplomatic outreach against Pakistan's support for terrorism
